CDSCO approves AstraZeneca's anti-liver cancer drug combination

The primary endpoint was overall survival (OS) for the combination versus sorafenib and secondary endpoints included OS for durvalumab versus sorafenib, objective response rate and progression-free survival (PFS) for the combination and for Durvalumab alone. The trial showed a positive and significant benefit for OS for the combination of Tremelimumab & Durvalumab vs Sorafenib.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pEGfrod
via IFTTT